UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): August 12, 2025 |
AVITA Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-39059 |
85-1021707 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
28159 Avenue Stanford Suite 220 |
|
Valencia, California |
|
91355 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 661 367-9170 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share |
|
RCEL |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.02. Unregistered Sales of Equity Securities.
On August 12, 2025, AVITA Medical, Inc. (the “Company”) entered into a placement agreement (the “Placement Agreement”) with MST Financial Services Pty Limited for a placement (the “Placement”) to Australian institutional and professional investors of 17,201,886 CHESS Depositary Interests (“CDIs”), at an issue price of approximately AU$1.32 per CDI, with five CDIs representing one share of Common Stock. The Company expects to receive aggregate proceeds of approximately US$15 million (A$22.7 million) and to pay placement agent fees, in a combination of cash and CDIs, for an approximate value of US$0.8 million, in connection with the Placement. The Placement is expected to close on or about August 19, 2025.
The CDIs to be issued and sold in the Placement will be deemed to be securities exempt from registration under the Securities Act of 1933, as amended, in reliance on Regulation S promulgated thereunder, as transactions by an issuer in an offering made outside the United States. Legends or notices will be affixed to the securities issued in reliance on Regulation S.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
AVITA Medical, Inc |
|
|
|
|
Date: |
August 18, 2025 |
By: |
/s/ David O'Toole |
|
|
|
David O'Toole
Chief Financial Officer |